|
GSK PLC said on Tuesday its asthma drug was accepted for review in China, while it also reported a trial for a drug to treat an infectious disease met its primary endpoint. The pharmaceutical company, based in Brentford, England, said asthma drug Nucala was being reviewed by the China National Medial Products Administration. If approved, Nucala would become the first severe asthma treatment for the Chinese adult and adolescent patients. Around 46 million adults in China suffer from asthma, with 6% experiencing a severe form of the condition. Also on Tuesday, GSK said its MenABCWY vaccine had met all 11 primary endpoints of its phase three trial, after showing a clinically meaningful immune response. The vaccine, which is administered in two doses and given six months apart in people aged between 1025 years, would be used to prevent invasive meningococcal disease, the company said. Meningococcal disease can cause meningitis. Chief Scientific Officer Tony Wood said the routine use of the vaccine could drive a ‘significant public health impact’, while also building on the company’s ‘leadership in meningococcal vaccines’. GSK shares were up 0.5% at 1,383.60 pence in London Tuesday morning. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
